###begin article-title 0
###xml 123 126 <span type="species:ncbi:10116">Rat</span>
Islet Endothelial Activation and Oxidative Stress Gene Expression Is Reduced by IL-1Ra Treatment in the Type 2 Diabetic GK Rat
###end article-title 0
###begin p 1
Conceived and designed the experiments: GL NK JC AG CN MC FS JLP NJ MD JE FHD. Performed the experiments: GL MHG NK JC AG CN MC FS JLP NJ JE FHD. Analyzed the data: GL JCI MK MD JE FHD. Contributed reagents/materials/analysis tools: BP. Wrote the paper: GL JCI MD JE FHD.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 89 94 <span type="species:ncbi:9606">human</span>
###xml 340 343 <span type="species:ncbi:10116">rat</span>
Inflammation followed by fibrosis is a component of islet dysfunction in both rodent and human type 2 diabetes. Because islet inflammation may originate from endothelial cells, we assessed the expression of selected genes involved in endothelial cell activation in islets from a spontaneous model of type 2 diabetes, the Goto-Kakizaki (GK) rat. We also examined islet endotheliuml/oxidative stress (OS)/inflammation-related gene expression, islet vascularization and fibrosis after treatment with the interleukin-1 (IL-1) receptor antagonist (IL-1Ra).
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 792 799 792 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 112 123 <span type="species:ncbi:10116">Wistar rats</span>
###xml 141 145 <span type="species:ncbi:10116">rats</span>
###xml 787 791 <span type="species:ncbi:10116">rats</span>
Gene expression was analyzed by quantitative RT-PCR on islets isolated from 10-week-old diabetic GK and control Wistar rats. Furthermore, GK rats were treated s.c twice daily with IL-1Ra (Kineret, Amgen, 100 mg/kg/day) or saline, from 4 weeks of age onwards (onset of diabetes). Four weeks later, islet gene analysis and pancreas immunochemistry were performed. Thirty-two genes were selected encoding molecules involved in endothelial cell activation, particularly fibrinolysis, vascular tone, OS, angiogenesis and also inflammation. All genes except those encoding angiotensinogen and epoxide hydrolase (that were decreased), and 12-lipoxygenase and vascular endothelial growth factor (that showed no change), were significantly up-regulated in GK islets. After IL-1Ra treatment of GK rats in vivo, most selected genes implied in endothelium/OS/immune cells/fibrosis were significantly down-regulated. IL-1Ra also improved islet vascularization, reduced fibrosis and ameliorated glycemia.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 3 6 <span type="species:ncbi:10116">rat</span>
###xml 528 532 <span type="species:ncbi:10116">rats</span>
GK rat islets have increased mRNA expression of markers of early islet endothelial cell activation, possibly triggered by several metabolic factors, and also some defense mechanisms. The beneficial effect of IL-1Ra on most islet endothelial/OS/immune cells/fibrosis parameters analyzed highlights a major endothelial-related role for IL-1 in GK islet alterations. Thus, metabolically-altered islet endothelium might affect the beta-cell microenvironment and contribute to progressive type 2 diabetic beta-cell dysfunction in GK rats. Counteracting islet endothelial cell inflammation might be one way to ameliorate/prevent beta-cell dysfunction in type 2 diabetes.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 387 390 387 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Creager1">[1]</xref>
###xml 542 545 542 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Brownlee1">[2]</xref>
The endothelium plays an important role in the regulation of hemostasis, blood flow, maintenance of vascular architecture and mononuclear cell migration, all of primary significance in atherogenesis. The diabetic state is well known to be associated with macrovascular complications such as atherosclerosis and medial calcifications that lead to increased risk of cardiovascular disease [1]. In addition, a diabetic-specific microvascular disease is at work in the retina (retinopathy), kidney (glomerulopathy) and vasa nervorum (neuropathy) [2].
###end p 9
###begin p 10
###xml 251 254 251 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Hayden1">[3]</xref>
###xml 256 259 256 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Kim1">[4]</xref>
###xml 437 440 437 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Hayden1">[3]</xref>
###xml 442 445 442 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Clark1">[5]</xref>
###xml 446 449 446 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Ehses1">[7]</xref>
###xml 570 573 570 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-HomoDelarche1">[6]</xref>
###xml 575 578 575 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Ehses2">[8]</xref>
###xml 580 583 580 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Donath1">[9]</xref>
###xml 717 720 717 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-HomoDelarche1">[6]</xref>
###xml 722 725 722 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Ehses1">[7]</xref>
###xml 870 874 870 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Nakamura1">[10]</xref>
###xml 876 880 876 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Li1">[11]</xref>
###xml 428 436 <span type="species:ncbi:9606">patients</span>
###xml 563 569 <span type="species:ncbi:9606">humans</span>
###xml 634 637 <span type="species:ncbi:10116">rat</span>
###xml 842 846 <span type="species:ncbi:10116">rats</span>
###xml 864 869 <span type="species:ncbi:10090">mouse</span>
Until now, the pancreatic islets have been only rarely considered as being a possible "end-organ" of type 2 diabetes (T2D). However, the islet has been shown to undergo significant remodelling concurrently or even earlier than other end-organs in T2D [3], [4]. Indeed, some studies have demonstrated the presence of fibrosis in various spontaneous T2D animal models, and also the presence of amyloid deposits in type 2 diabetic patients [3], [5]-[7]. Moreover, we showed recently that inflammation is present in the islets of type 2 diabetic animal models and in humans [6], [8], [9]. In the spontaneously diabetic Goto-Kakizaki (GK) rat, we suggested that these islet alterations were reminiscent of microangiopathy [6], [7]. Others, using electron microscopy, have described signs of microangiopathy in young but normoglycemic Zucker fatty rats and in the db/db mouse [10], [11].
###end p 10
###begin p 11
###xml 402 405 402 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Creager1">[1]</xref>
###xml 406 409 406 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Hayden1">[3]</xref>
###xml 411 415 411 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-CallesEscandon1">[12]</xref>
###xml 416 420 416 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Rojas1">[14]</xref>
###xml 1410 1413 1406 1409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Creager1">[1]</xref>
###xml 1415 1419 1411 1415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Staels1">[15]</xref>
Hyperglycemia and some other associated metabolic derangements (increased free fatty acids (FFA) and/or insulin resistance), which may precede hyperglycemia, mediate abnormal endothelial cell (EC) function via increased oxidative stress (OS), disturbances of intracellular signal transduction (such as protein kinase C activation) and activation of receptors for advanced glycation end-products (RAGE) [1]-[3], [12]-[14]. These molecular events lead to: 1) decreased nitric oxide (NO) availability associated with increased levels of endothelin-1 (ET-1) and angiotensin II (A-II) with resulting vasoconstriction and its consequences on blood flow and vascular smooth muscle cell (VSMC) growth; 2) activation of transcription factors such as nuclear factor kappa B (NF-kappaB) and activator protein-1 (AP-1), which increases the expression of cellular adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). It also stimulates the production of cytokines, for example, IL-1 and chemokines, such as monocyte/macrophage chemoattractant protein (MCP-1), leading to local inflammation, leukocyte attraction/migration and reactive oxygen species (ROS) production; 3) increased production of prothrombotic/dysfibrinolytic factors, such as tissue factor and plasminogen activator inhibitor-1 (PAI-1), which induce hypercoagulation and platelet aggregation [1], [15].
###end p 11
###begin p 12
###xml 126 130 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Rojas1">[14]</xref>
###xml 225 229 225 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Ceriello1">[16]</xref>
###xml 230 234 230 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Schalkwijk1">[18]</xref>
###xml 348 352 348 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Nishikawa1">[19]</xref>
###xml 353 357 353 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Meigs1">[21]</xref>
###xml 544 547 544 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-HomoDelarche1">[6]</xref>
###xml 629 633 629 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Schulze1">[22]</xref>
###xml 824 828 813 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Mantovani1">[23]</xref>
###xml 829 833 818 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Tedgui1">[28]</xref>
###xml 416 420 <span type="species:ncbi:10116">rats</span>
Overall vascular function is dependent upon the balance of pro-/antioxidant mechanisms, which determines endothelial function [14]. Considerable evidence demonstrates that OS plays a central role in the pathology of diabetes [16]-[18]. Among other factors including obesity and insulin resistance, hyperglycemia alone is able to directly induce OS [19]-[21]. Diabetes starts at around 4 weeks of age (weaning) in GK rats. After 3 months of mild hyperglycemia, GK islets show an upregulation of the gene encoding thioredoxin-interacting protein [6], which is induced by hyperglycemia and inhibits thioredoxin antioxidant function [22]. Also, ROS are involved in the mechanism of action of pro-inflammatory cytokines, such as IL-1beta and tumor necrosis factor-alpha (TNF-alpha), known to be produced by EC and to target them [23]-[28]. Therefore, based on the data presented above, we hypothesized that T2D islet inflammation might have originated from EC activation.
###end p 12
###begin p 13
###xml 507 511 507 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Larsen1">[29]</xref>
###xml 512 516 512 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Apostolakis1">[31]</xref>
###xml 671 678 671 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 45 49 <span type="species:ncbi:10116">rats</span>
###xml 612 616 <span type="species:ncbi:10116">rats</span>
Here, we assessed in 10-week-old diabetic GK rats and Wistar controls: 1) different circulating parameters linked to EC dysfunction, OS, inflammation, and atherosclerosis; 2) the expression of selected genes known to be involved in EC activation in freshly isolated islets; 3) the effect of 1-month treatment with IL-1Ra on islet expression of genes linked to endothelium, OS and extracellular matrix proteins, and islet vascularization and fibrosis. IL-1Ra has already been used in T2D and atherosclerosis [29]-[31]. Our data showed that endothelial activation is present in islets from 10-week-old diabetic GK rats, concomitantly with inflammation/OS. Moreover, IL-1Ra in vivo dampened these events, ameliorating islet vascularization, reducing fibrosis and improving glycemia.
###end p 13
###begin title 14
Results
###end title 14
###begin title 15
###xml 53 57 <span type="species:ncbi:10116">rats</span>
Dyslipidemia and signs of systemic OS in diabetic GK rats
###end title 15
###begin p 16
###xml 96 103 96 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006963-t001">Table 1</xref>
###xml 266 270 266 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Portha1">[32]</xref>
###xml 878 882 874 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Lentz1">[33]</xref>
###xml 884 888 880 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Sharma1">[34]</xref>
###xml 1056 1060 1052 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Hamelet1">[35]</xref>
###xml 73 77 <span type="species:ncbi:10116">rats</span>
###xml 511 522 <span type="species:ncbi:10116">Wistar rats</span>
###xml 1450 1454 <span type="species:ncbi:10116">rats</span>
Metabolic parameters for 10-week-old male control Wistar and diabetic GK rats are summarized in Table 1. The body weight of diabetic animals was significantly lower than controls. They displayed mildly but significantly elevated fed blood glucose and insulin levels [32]. They also showed hyperleptinemia and significantly increased circulating levels of triglycerides, FFA, total cholesterol and high density lipoproteins (HDL) cholesterol. Their total cholesterol/HDL cholesterol ratio was similar to that of Wistar rats. The glutathione redox state was significantly lower in GK than Wistar red blood cells (RBC), with comparable equivalent reduced glutathione contents (Eq GSH). Plasma alpha-tocopherol level was significantly higher in GK animals than controls. Concomitantly, the plasma homocysteine level, an independent risk factor in the development of atherosclerosis [33], [34], was significantly lower. Moreover, the activity of paraoxonase-1 (PON-1), an HDL-associated lipo-lactamase, whose activity is negatively correlated with homocysteine [35], was signicantly higher in diabetic than control animals. However, circulating cytokines/chemokines levels, such as GRO1/KC (or CXCL1, the rodent equivalent of IL-8), MCP-1 (CCL2), MIP-1alpha (macrophage inflammatory protein-1alpha or CCL3) and IL-6 were not significantly different at this age between both groups. Therefore, in addition to mild basal hyperglycemia, 10-week-old adult GK rats also exhibited hyperlipidemia, blood OS (as reflected by oxidized RBC glutathione redox state), but had already mounted blood antioxidant defense (high alpha-tocopherol level and PON-1 activity).
###end p 16
###begin title 17
###xml 67 71 <span type="species:ncbi:10116">rats</span>
Metabolic data for 10-week-old control Wistar and diabetic GK male rats.
###end title 17
###begin p 18
###xml 834 835 822 823 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 900 901 888 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Glucose, insulin, leptin, lipids, cytokine and chemokine levels were determined in serum. Alpha-tocopherol and homocysteine levels, and paraoxonase-1 (PON-1) activity were determined in plasma. Glutathione redox state (% of reduced glutathione (GSH)) and GSH content (Eq GSH) were determined in red blood cells (RBC). Glucose, insulin, leptin: n = 7 per group; lipids: n = 9 per group; cytokines/chemokines: n = 7 per group; alpha-tocopherol, glutathione redox state and GSH content (n = 7-13 per group) and homocysteine and PON-1: n = 7-8 per group. All parameters were assayed under fed conditions. FFA (free fatty acids); HDL: high density lipoproteins; GRO1/KC/CXCL1: rodent equivalent of IL-8; MCP-1/CCL2: monocyte/macrophage chemoattractant protein; MIP-1alpha/CCL3: macrophage inflammatory protein-1alpha; IL-6, interleukin-6. *p<0.05 versus age-matched Wistar group, as analyzed by Student's t-test.
###end p 18
###begin title 19
###xml 44 48 <span type="species:ncbi:10116">rats</span>
Islet endothelial activation in diabetic GK rats
###end title 19
###begin p 20
###xml 394 397 394 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Creager1">[1]</xref>
###xml 399 403 399 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Staels1">[15]</xref>
###xml 405 409 405 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Stocker1">[25]</xref>
###xml 411 415 411 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Tedgui1">[28]</xref>
###xml 417 421 417 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Michelsen1">[36]</xref>
###xml 422 426 422 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Barlic1">[38]</xref>
###xml 555 562 555 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006963-t002">Table 2</xref>
###xml 2037 2041 <span type="species:ncbi:10116">rats</span>
Hyperglycemia is well recognized to be associated with increased arterial wall inflammation, reflected by increased expression of anti-fibrinolytic components, vascular cell adhesion molecules, renin-angiotensin system (RAS) factors, agents involved in OS, vascular tone and angiogenesis, and also of cytokines, chemokines, Toll-like receptors (TLRs) and molecules involved in their signalling [1], [15], [25], [28], [36]-[38]. Therefore, we selected 32 genes encoding molecules belonging to these different classes. Expression of these genes is shown in Table 2. Twenty-eight of 32 of the selected genes were significantly over-expressed. These genes encoded the following molecules: 1) anti-fibrinolysis system: PAI-1; 2) vascular adhesion molecules: E-selectin (E-SELE), ICAM-1, platelet-endothelial cell-adhesion molecule-1 (PECAM-1) and VECAM-1; 3) RAS: angiotensin-converting enzyme-1 (ACE-1) and angiotensin receptor-1alpha (AGTR-1alpha); 4) vascular tone/OS/angiogenesis components: cyclo-oxygenase-2 (COX-2), endothelial nitric oxide synthase (eNOS), endothelin-1 (ET-1), heme-oxygenase-1 (HO-1), hypoxia-induced factor-1alpha (HIF-1alpha), NADPH-oxidase-2 (NOX-2), prostacyclin synthase; 5) cytokines and growth factors: IL-1beta, IL-1Ra, IL-6, transforming growth factor-beta (TGF-beta), tumor necrosis factor-alpha (TNF-alpha); 6) chemokines: GRO1/KC, MCP-1, and MIP-1alpha; 7) cellular pathways for cytokines and TLRs: caspase-1, TLR-2, TLR-4, myeloid differentiation primary response protein MyD88, NF-kappaB and inductible nitric oxide synthase (iNOS). The expression of 2 genes of 32 was found to be significantly decreased, one encoding a molecule belonging to RAS: angiotensinogen and the other encoding soluble (cytoplasmic) epoxide hydrolase (sEH), involved in vascular tone, OS, inflammation and angiogenesis. Finally, the gene expression for the pro-oxidant 12-lipoxygenase (12-LOX) and the pro-angiogenic factor vascular endothelial growth factor (VEGF) was not modified. Thus, islets from 10-week-old diabetic GK rats are characterized by increased mRNA levels of molecules involved in dysfibrinolysis, endothelium cell adhesion, vascular tone, OS and inflammation.
###end p 20
###begin title 21
Expression of genes encoding factors involved in endothelium activation and inflammation in GK islets.
###end title 21
###begin p 22
###xml 329 330 327 328 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 353 354 351 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 89 93 <span type="species:ncbi:10116">rats</span>
Total RNA was extracted from freshly isolated islets of 2.5-month-old male Wistar and GK rats and quantitative RT-PCR was performed for the indicated genes and normalized to a housekeeping gene (rpL19 or Ef1a). Data are means+/-SEM of 5-6 different islet isolations per group except for caspase-1 and epoxide hydrolase-2 (n = 3).*p<0.05 using Student's t-test.
###end p 22
###begin title 23
Beneficial effect of IL-1Ra on glycemia and expression of genes selected for endothelial activation, OS and ECM, and on vascularization and fibrosis in GK islets
###end title 23
###begin p 24
###xml 80 84 80 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Mantovani1">[23]</xref>
###xml 85 89 85 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Tedgui1">[28]</xref>
###xml 180 184 177 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Tedgui1">[28]</xref>
###xml 186 190 183 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Dejana1">[39]</xref>
###xml 192 196 189 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Mantovani2">[40]</xref>
###xml 313 317 <span type="species:ncbi:10116">rats</span>
###xml 426 430 <span type="species:ncbi:10116">rats</span>
Endothelial activation, OS and mechanisms of cytokine action are tightly linked [23]-[28]. IL-1beta, produced by EC among other cells, is involved in microangiopathy/atherogenesis [28], [39], [40]. Therefore, we administered IL-1Ra, its natural antagonist, s.c. twice daily at 50 mg/kg (i.e. 100 mg/kg/day) to GK rats, from 4 weeks (weaning and onset of diabetes) to 8 weeks of age. At the end of treatment, IL-1Ra-treated GK rats showed a significantly lower glycemia than GK saline (controls): 8.8+/-0.3 mM (n = 7) and 7.9+/-0.1 mM (n = 8, p<0.05), respectively.
###end p 24
###begin p 25
###xml 74 81 74 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006963-g001">Fig. 1A</xref>
###xml 349 351 349 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs</italic>
###xml 3 6 <span type="species:ncbi:10116">rat</span>
GK rat IL-1Ra treatment down-regulated 80% of selected genes. As shown in Fig. 1A, IL-1Ra treatment significantly (except otherwise stated) decreased GK islet expression of genes encoding: PAI-1 (-61%), VCAM-1 (-68%, ns), ACE-1 (-74%), ET-1 (Edn1, -54%), NOX-2 (-67%), COX-2 (-60%), iNOS (-54%), prostacyclin synthase (Ptgis, -48%), and eNOS (-55%) vs Wistar controls. However, IL-1Ra treatment did not significantly reduce islet endothelial gene expression for E-selectin (Sele) and HIF-1alpha.
###end p 25
###begin title 26
IL-1Ra treatment reduces the expression of most of the selected genes for endothelial activation, oxidative stress, myeloid cells, and fibrosis in GK islets.
###end title 26
###begin p 27
###xml 319 320 319 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 343 344 343 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 40 44 <span type="species:ncbi:10116">rats</span>
Pancreatic islets were isolated from GK rats following 1-month-treatment with IL-1Ra by s.c. injections (GK saline n = 6, GK IL-1Ra (100 mg/kg/day), n = 5). For each animal, total RNA was extracted from isolated islets and quantitative RT-PCR was performed for the indicated genes, and expressed relative to GK saline. *p<0.05 using Student's t-test.
###end p 27
###begin p 28
###xml 85 92 85 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006963-g001">Fig. 1B</xref>
###xml 202 206 202 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Grankvist1">[41]</xref>
###xml 208 212 208 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Lenzen1">[42]</xref>
###xml 305 312 302 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 312 316 309 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Laybutt1">[43]</xref>
###xml 353 357 350 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Lacraz1">[44]</xref>
###xml 1028 1029 1025 1026 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1030 1031 1027 1028 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1559 1563 1552 1556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Haddad1">[45]</xref>
###xml 1716 1720 1709 1713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Jonas1">[46]</xref>
###xml 1735 1739 1728 1732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Willis1">[47]</xref>
###xml 1751 1755 1744 1748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Hibbs1">[48]</xref>
###xml 1757 1761 1750 1754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Terry1">[49]</xref>
###xml 1808 1812 1801 1805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Ishikawa1">[50]</xref>
###xml 1977 1981 1970 1974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Kwak1">[51]</xref>
###xml 388 392 <span type="species:ncbi:10116">rats</span>
###xml 828 831 <span type="species:ncbi:9685">Cat</span>
The effects of IL-1Ra treatment on genes encoding antioxidant molecules are shown in Fig. 1B. Beta-cells appear to be especially vulnerable to ROS attacks due to their low levels of antioxidant enzymes [41], [42]. To compensate for such vulnerability, diabetic beta cells may upregulate antioxidant genes in vivo[43], as we recently showed in GK islets [44]. Here, IL-1Ra treatment of GK rats was able to down-regulate the expression of some of these genes but not all of them. First, the gene expression of one of the main stress-activated mitochondrial enzymes, superoxide dismutase 2 was decreased (Sod2, -63%). This enzyme represents the first-line of defense against superoxide anions generated by the mitochondria. However, IL-1Ra did not modify the expression of Sod1 gene. IL-1Ra further reduced significantly catalase (Cat, -34%), but not glutathione peroxidase 1 (Gpx1), nor thioredoxin 1 (Txd1), or peroxiredoxin 1 (Prdx1). Those genes encode molecules involved in further reduction of superoxide-derived compounds (H2O2). IL-1Ra treatment down-regulated the expression of genes encoding gamma-glutamylcysteine ligase catalytic subunit (Gclc, -42%) and glutathione reductase (Gsr, -31%), both of which contribute to maintain the content of GSH, an antioxidant thiol, whose mechanisms include: 1) an antioxidant potential mediated by the peroxidase-coupled reaction; 2) regulation of cellular sulfhydryl status and redox equilibrium; 3) regulation of expression/activation of redox-sensitive transcription factors induced by stress-evoked responses [45]. IL-1Ra treatment also significantly lowered the gene encoding HO-1 (Hmox1, -49%), an antioxidant induced by supra-physiological glucose concentrations [46], inflammation [47], cytokines [48], [49], and oxidative low density lipoproteins (LDL) [50]. Finally, IL-1Ra treatment down-regulated the expression of NF-E2-related factor (Nrf2, -47%), which drives the expression of several genes, such as Gclc and Hmox1 [51].
###end p 28
###begin p 29
###xml 12 18 12 18 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006963-g001">Fig.1C</xref>
###xml 213 217 206 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Ehses3">[52]</xref>
###xml 397 400 390 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-HomoDelarche1">[6]</xref>
###xml 792 794 785 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs</italic>
###xml 809 812 802 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-HomoDelarche1">[6]</xref>
###xml 912 919 905 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006963-g001">Fig. 1D</xref>
As shown in Fig.1C, IL-1Ra reduced mRNA islet levels of TLR4 (-55%), MyD88 (-22%) and NF-kappaB (-48%), in addition to mRNA down-regulation of various cytokines/chemokines (including IL-1beta), as shown elsewhere [52]. Not surprisingly therefore, IL-1Ra treatment also down-regulated the expression of genes encoded by macrophages or immature myeloid cells, which infiltrate GK islets at this age [6]. For example, the mRNA levels of MHC (major histocompatibility complex) class II (H2-Ea), CD53, and CD74 (macrophage inhibitory receptor or MIF) were strongly reduced: -70%, -40%, and -78%, respectively). Moreover, the genes encoding the main three extracellular matrix proteins constituting GK islet fibrosis (collagen I, collagen III and fibronectin, whose genes were over-expressed in GK vs Wistar islets [6]) were down-regulated after IL-1Ra treatment (Col1a1, -48%, Col3a1, -45%; Fn1, -49%, respectively) (Fig. 1D).
###end p 29
###begin p 30
###xml 170 173 170 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-HomoDelarche1">[6]</xref>
###xml 250 258 250 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006963-g002">figure 2</xref>
###xml 301 304 301 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-HomoDelarche1">[6]</xref>
###xml 325 329 <span type="species:ncbi:10116">rats</span>
Finally, we performed immunohistochemistry for von Willebrand factor (VWF), an EC marker, and for fibronectin, a main component of GK islet fibrosis, also produced by EC [6]. Von Willebrand factor and fibronectin islet labeling examples are shown in figure 2 (panels A and B). As previously described [6], islets of adult GK rats are extremely heterogeneous, compared to age-matched Wistar islets: they showed different degrees of endothelial alteration and fibrosis. More precisely, GK islet vascularization appears more or less hypertrophied or even greatly disorganized. One month of IL-1Ra treatment significantly reduced labeling of GK islet alterations, as shown for both VWF and fibronectin (-53% and -69%, respectively).
###end p 30
###begin title 31
IL-1Ra treatment improves vascularization and reduces fibrosis in GK islets.
###end title 31
###begin p 32
###xml 747 748 747 748 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 771 772 771 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 142 146 <span type="species:ncbi:10116">rats</span>
###xml 189 193 <span type="species:ncbi:10116">rats</span>
###xml 309 313 <span type="species:ncbi:10116">rats</span>
###xml 461 465 <span type="species:ncbi:10116">rats</span>
###xml 607 611 <span type="species:ncbi:10116">rats</span>
Immunohistochemistry was performed for von Willebrand factor (VWF) (A) and fibronectin (B) in pancreas of young adult untreated Wistar and GK rats, and of s.c. saline- or IL-1Ra-treated-GK rats. The border of each islet is defined by the dashed line. As shown in panel A, VWF-labeled islets from untreated GK rats are extremely heterogeneous in terms of vascularization and extent of fibrosis, when compared to Wistar controls. In saline- and IL-1Ra-treated GK rats, immunolabeled islet area for VWF or fibronectin was quantified for each islet and expressed as to the corresponding islet surface (n = 3 GK rats for both treatment groups, n = 25-40 islets). Islets analyzed for quantification showed unchanged islet area between treatment groups. *p<0.05 using Student's t-test.
###end p 32
###begin title 33
Discussion
###end title 33
###begin p 34
###xml 335 339 335 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Nakamura1">[10]</xref>
###xml 341 345 341 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Li1">[11]</xref>
###xml 347 351 347 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Masuyama1">[53]</xref>
###xml 353 357 353 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Ko1">[54]</xref>
###xml 425 428 425 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Clark1">[5]</xref>
###xml 528 531 528 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Ehses1">[7]</xref>
###xml 748 755 748 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 214 218 <span type="species:ncbi:10116">rats</span>
###xml 230 234 <span type="species:ncbi:10090">mice</span>
###xml 416 424 <span type="species:ncbi:9606">patients</span>
###xml 632 636 <span type="species:ncbi:10116">rats</span>
The origin of the recently recognized islet inflammation in T2D is still an open question. A few studies in various spontaneous T2D animal models (Zucker diabetic fatty, Otsuka Long-Evans Tokushima fatty and Torii rats, and db/db mice) indicated islet vessel alterations (leakage, hemorrhage), anomalies of blood flow, microangiopathy [10], [11], [53], [54] or even amyloid deposits along vessels in type 2 diabetic patients [5]. We hypothesized that islet inflammation might have originated from EC activation (for review, see [7]). Using a molecular approach, we demonstrate here, for the first time, that 10-week-old diabetic GK rats show increased markers of endothelial microvessel activation associated with inflammation in islets. Moreover, in vivo IL-Ra treatment reduced most of these molecular and vascular alterations, islet fibrosis and glycemia.
###end p 34
###begin p 35
###xml 136 140 136 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Cheng1">[55]</xref>
###xml 141 145 141 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Sena1">[59]</xref>
###xml 436 440 436 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Kimura1">[60]</xref>
###xml 561 565 561 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Cheng1">[55]</xref>
###xml 567 571 567 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Harris1">[57]</xref>
###xml 572 576 572 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Sena1">[59]</xref>
###xml 61 64 <span type="species:ncbi:10116">rat</span>
Endothelial dysfunction has already been described in old GK rat macrovessels (mesenteric artery, thoracic aorta and cerebral arteries) [55]-[59]. These studies showed adhesion molecule gene overexpression, pronounced renal perivascular monocyte/macrophage infiltration, increased vascular OS, and RAS and ET-1 involvement. Moreover, GK macrophages exhibit a pro-inflammatory phenotype associated with the pathogenesis of atherogenesis [60]. Alpha-lipoic acid, AGTR-1 and ET-1 antagonists have been shown to provide vasoprotective effects in these macrovessels [55], [57]-[59]. Here, we extend the observation to alterations of the islet microvascular bed in an early stage of the GK disease development.
###end p 35
###begin p 36
###xml 384 388 384 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Wallis1">[61]</xref>
###xml 390 394 390 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Argoud1">[62]</xref>
###xml 633 637 633 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Wallis1">[61]</xref>
###xml 735 739 735 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Beltowski1">[63]</xref>
###xml 1031 1035 1031 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Lentz1">[33]</xref>
###xml 1037 1041 1037 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Sharma1">[34]</xref>
###xml 1043 1047 1043 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Holven1">[64]</xref>
###xml 1296 1300 1296 1300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Mackness1">[65]</xref>
###xml 1302 1306 1302 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Aviram1">[66]</xref>
###xml 1445 1449 1445 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Hamelet1">[35]</xref>
###xml 1712 1716 1712 1716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Rozenberg1">[67]</xref>
###xml 2121 2125 2117 2121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Beltowski2">[68]</xref>
###xml 39 43 <span type="species:ncbi:10116">rats</span>
###xml 255 259 <span type="species:ncbi:10116">rats</span>
###xml 311 315 <span type="species:ncbi:10116">rats</span>
###xml 642 646 <span type="species:ncbi:10116">rats</span>
###xml 843 847 <span type="species:ncbi:10116">rats</span>
###xml 849 857 <span type="species:ncbi:9606">Patients</span>
###xml 1094 1098 <span type="species:ncbi:10116">rats</span>
###xml 1408 1413 <span type="species:ncbi:10090">mouse</span>
###xml 1488 1492 <span type="species:ncbi:10116">rats</span>
###xml 1619 1623 <span type="species:ncbi:10090">mice</span>
###xml 1840 1844 <span type="species:ncbi:10116">rats</span>
###xml 1871 1875 <span type="species:ncbi:10116">rats</span>
###xml 2109 2120 <span type="species:ncbi:10116">Wistar rats</span>
###xml 2153 2157 <span type="species:ncbi:10116">rats</span>
###xml 2313 2317 <span type="species:ncbi:10116">rats</span>
###xml 2387 2391 <span type="species:ncbi:10116">rats</span>
As expected, 8-10-week-old diabetic GK rats showed mild hyperglycemia, hyperinsulemia and hyperlipidemia. However, it should be mentioned that, at this age (around onset of insulin resistance), hyperinsulinemia may be observed or not from one batch of GK rats to another. Our data confirm that male diabetic GK rats exhibit increased levels of triglycerides, FFA, cholesterol and HDL [61], [62]. Notably, extensive physiological screening in both sexes of congenics revealed the existence of GK variants at the locus Nidd/gk5, independently responsible for significantly enhanced insulin secretion and altered cholesterol metabolism [61]. GK rats had marked hyperleptinemia, classically associated with obesity and/or hyperinsulinemia [63]. Concomitantly, peripheral OS, as reflected by oxidized RBC glutathione redox state, was present in GK rats. Patients with high circulating homocysteine levels, an independent risk factor of atherosclerosis development, have an impaired ability to induce cholesterol efflux from macrophages [33], [34], [64]. Homocysteine, unexpectedly lower in diabetic rats than in controls, might be responsible for the higher systemic GK cholesterol levels. PON-1 is an antioxidant agent and anti-atherogenic HDL-associated enzyme, which prevents LDL and HDL oxidation [65], [66]. Homocysteine has been demonstrated to be negatively correlated to the plasma activity of PON-1 in a mouse model of homocysteine disorder [35]. This is also the case in diabetic GK rats, which had higher plasma PON-1 arylesterase activity than Wistar. In this regard, it should be noted that increasing PON-1 in mice attenuated diabetes-induced macrophage OS, diabetes development and decreased mortality [67]. Therefore, high circulating PON-1 activity together with enhanced alpha-tocopherol (vitamin E) in 10-week-old diabetic GK rats, might suggest that these rats had already installed a systemic antioxidant defense in the lipophilic plasma compartment. The latter might be characterized by some degree of leptin resistance, because of the decreasing effect of leptin on plasma PON-1 activity in Wistar rats [68], and hyperleptinemia in GK rats. This might explain why, despite high circulating levels of the pro-inflammatory/pro-oxidant leptin, systemic cytokine/chemokine levels were similar in GK rats and Wistar controls, while the levels of some of them was high in GK rats before weaning (see below).
###end p 36
###begin p 37
###xml 275 278 275 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Creager1">[1]</xref>
###xml 279 282 279 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Hayden1">[3]</xref>
###xml 284 288 284 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-CallesEscandon1">[12]</xref>
###xml 289 293 289 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Rojas1">[14]</xref>
###xml 370 373 370 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Creager1">[1]</xref>
###xml 375 378 375 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Brownlee1">[2]</xref>
###xml 380 384 380 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Brownlee2">[17]</xref>
###xml 498 502 498 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Shanmugam1">[69]</xref>
###xml 602 606 602 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Busik1">[70]</xref>
###xml 824 828 824 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Beltowski1">[63]</xref>
###xml 830 834 830 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Kim2">[71]</xref>
###xml 836 840 836 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Higuchi1">[72]</xref>
###xml 842 848 842 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006963-g003">Fig. 3</xref>
###xml 925 929 925 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Dedon1">[73]</xref>
###xml 1059 1063 1053 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Donath2">[74]</xref>
###xml 1160 1163 1151 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Ehses1">[7]</xref>
Molecular signs of GK islet endothelial activation and OS might not only derive from mild chronic hyperglycemia, but also from associated metabolic disorders, such as increased circulating FFA and cholesterol levels and/or insulin resistance, which can precede hyperglycemia [1]-[3], [12]-[14]. Hyperglycemia alone is recognized for a long time to be deleterious for EC [1], [2], [17], while it induces pro-inflammatory cytokine/chemokine expression in monocytes and increases their adhesion to EC [69], where hyperglycemia-induced ROS toxicity is dependent on paracrine factor release, like cytokines [70]. High levels of FFA signaling through TLR receptors, cholesterol, leptin and A-II are also able to stimulate cytokine/chemokine release from EC and/or vascular smooth muscle cells, consequently increasing vascular OS [63], [71], [72] (Fig. 3). Then, inflammatory cells migrate and produce cytokines/chemokines and ROS [73], which might alter beta-cells. Also, beta-cells are able to produce IL-1 and IL-Ra in the presence of glucose, FFA and/or leptin [74]. A vicious cycle is therefore initiated that will alter islet blood flow and beta-cell function [7], unless the islets are able to mount defense mechanisms.
###end p 37
###begin title 38
###xml 112 116 <span type="species:ncbi:10116">rats</span>
Proposed model illustrating the islet endothelial dysfunction and oxidative stress surrounding beta cells in GK rats.
###end title 38
###begin p 39
Elevated glucose, FFA and possibly cytokines induce endothelial activation at the islet level by eliciting reactive oxygen species (ROS) production and cytokine/chemokine release by endothelial cells and vascular smooth muscle cells. Once released, chemokines (CXCL1, CCL2, CCL3) attract/retain immune cells (monocytes, neutrophils), which further induce ROS and cytokine production around beta cells. In addition, cytokines as well as metabolic factors (high glucose and FFA) may act directly on beta cells to increase intracellular cytokines and ROS production with consecutive antioxidant defense response. Antagonizing IL-1 by IL-1Ra may inhibit endothelial activation/dysfunction and subsequent immune cells attraction/activation. IL-1Ra may also blunt IL-1 signaling in beta cells and subsequent ROS production and antioxidant defense response. CXCL1 (GRO1/KC, rodent equivalent of IL-8), CCL2 (MCP-1); CCL3 (MIP-1alpha); FFA (free fatty acids); IL-1beta, interleukin-1beta; IL-1Ra, interleukin-1 receptor antagonist; IL-6, interleukin-6; TNF-alpha, tumor necrosis factor-alpha.
###end p 39
###begin p 40
###xml 172 176 172 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Li1">[11]</xref>
###xml 178 182 178 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Masuyama1">[53]</xref>
###xml 237 241 237 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Shinohara1">[75]</xref>
###xml 294 296 294 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs</italic>
###xml 440 444 440 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-HomoDelarche2">[76]</xref>
###xml 630 634 630 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Calderari1">[77]</xref>
###xml 699 707 699 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in utero</italic>
###xml 720 724 720 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Libby1">[78]</xref>
###xml 948 952 948 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Lacraz1">[44]</xref>
###xml 1130 1134 1130 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-HomoDelarche2">[76]</xref>
###xml 141 145 <span type="species:ncbi:10116">rats</span>
###xml 193 197 <span type="species:ncbi:10116">rats</span>
###xml 1283 1287 <span type="species:ncbi:10116">rats</span>
Notably, islet capillary alterations and hemorrhage and signs of microangiopathy are already present in normoglycemic Torii and Zucker fatty rats, before onset of diabetes [11], [53]. In Torii rats, hyperlipidemia precedes hyperglycemia [75]. Similarly, we observed in prediabetic 7-day-old GK vs Wistar neonates, increased serum FFA levels and high cholesterol/HDL ratio together with elevated levels of chemokines (CXCL-1, CCL2 and CCL3) [76]. Because we also found higher circulating total cholesterol/HDL cholesterol ratio in E21.5 GK fetuses, our present hypothesis is that dyslipidemia, together with fetal GK hyperglycemia [77], initiates an islet microangiopathy/atherosclerosis process via in utero programming [78]. Such developmental metabolically-induced alterations may explain the high islet ROS levels associated with altered glutathione and thioredoxin-related gene expression recently observed in prediabetic 7-day-old GK neonates [44]. Thus, using oligo GEArrays targeted at endothelium and cardiovascular disease biomarkers, we showed a significant upregulation of genes encoding various inflammatory molecules [76], while the expression of genes encoding eNOS, E-selectin, VCAM-1, IL-1beta, IL-1Ra, IL-6, TNF-alpha, TLR-4 and MyD88 (upregulated in 10-week-old GK rats) was similar in 1-week-old prediabetic GK and Wistar islets (data not shown).
###end p 40
###begin p 41
###xml 565 568 562 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Ehses1">[7]</xref>
###xml 800 804 797 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Lamkanfi1">[79]</xref>
###xml 884 888 881 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Vink1">[37]</xref>
###xml 1667 1671 1640 1644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Lacraz2">[80]</xref>
After diabetes onset, however, we showed in GK islets that most of the selected 32 genes, which were up-regulated, encoded deleterious molecules involved in microangiopathy/atherosclerosis. Some molecules are more or less specific to endothelium (such as PAI-1, VCAM-1, E-selectin, PECAM-1 and eNOS), while part of endothelial activation includes inflammatory products not specific to endothelium. For example, cytokines and chemokines can be produced by different cell types, including EC, VSMC, macrophages, granulocytes, even beta-cells or other endocrine cells [7]. As hypothesized, there was an over-expression of genes encoding: anti-fibrinolytic agent, cellular adhesion molecules, cytokines/chemokines, growth factors and caspase 1, which cleaves pro-IL-1 and pro-IL-18 in their active forms [79]; and finally TLRs, which are stimulated by FFA and involved in atherosclerosis [37], and molecules involved in TLR and IL-1 signaling: MyD88, NF-kappaB and iNOS. The majority of molecules selected here are known to be modulated at the transcriptional level. However, a few of them, particularly NF-kappaB and HIF-1alpha, are regulated at the post-transcriptional and even post-translational level. Therefore, their mRNA levels do not correlate systematically with their transcriptional activity. Here, however, increased gene NF-kappaB expression was accompanied with more translational activity, because of its association with gene upregulation of IL-1 and iNOS, 2 molecules known to be under NF-kappaB regulation. In addition, mRNA levels of other genes under NF-kappaB regulation (antioxidant/antiapoptotic genes) were also elevated in 10-week-old GK islets [80].
###end p 41
###begin p 42
###xml 291 295 291 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Zheng1">[81]</xref>
###xml 343 346 343 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-HomoDelarche1">[6]</xref>
###xml 377 381 377 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Dedon1">[73]</xref>
###xml 524 528 524 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Wang1">[82]</xref>
###xml 643 647 643 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Bitar1">[56]</xref>
###xml 1095 1099 1095 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Bedard1">[83]</xref>
###xml 1288 1292 1288 1292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Ding1">[84]</xref>
###xml 1483 1487 1483 1487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Salehi1">[85]</xref>
###xml 1780 1784 1770 1774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Morgan1">[86]</xref>
###xml 1943 1947 1933 1937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Hayashi1">[87]</xref>
###xml 2151 2155 2141 2145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Linton1">[88]</xref>
###xml 2357 2361 2344 2348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Fujita1">[89]</xref>
###xml 122 126 <span type="species:ncbi:10090">mice</span>
###xml 569 573 <span type="species:ncbi:10116">rats</span>
###xml 1282 1287 <span type="species:ncbi:10090">mouse</span>
###xml 1730 1733 <span type="species:ncbi:10116">rat</span>
The GK islet iNos overexpression should be underlined on the basis of the following data: 1) studies using iNOS-deficient mice showed that iNOS plays an important role in the pathogenesis of vascular lesions characteristic of the early stages of diabetic retinopathy, preventing leukostasis [81]; 2) granulocytes infiltrate diabetic GK islets [6], express iNOS and produce ROS [73]; 3) granulocytes induce cardiomyocyte injury after myocardial ischemia/reperfusion by an iNOS-derived OS and peroxynitrite-mediated mechanism [82]; 4) in the aortic tissue of diabetic GK rats, superoxide production is increased but NO bioavailability decreased [56]. This is associated with elevated eNOS protein expression and low levels of its cofactor tetrahydrobiopterin, increased nitrosylated protein content and expression of the superoxide-generating enzyme NADPH oxidase (particularly, NOX-2). These data suggest that diabetes triggers ROS production from the NADPH oxidase, leading to tetrahydrobiopterin oxidation, eNOS uncoupling, and oxidative NO inactivation with subsequent peroxinitrite formation [83]. Moreover, increased expression of NOX-2 and eNOS mRNA and protein levels have been observed in the mesenteric arteries of streptozotocin-induced diabetic apolipoprotein-E-deficient mouse [84]. Similarly, genes encoding NOX-2 and eNOS were also up-regulated in our diabetic GK islets, together with elevated eNOS protein level (unpublished data) and increased GK islet NO production [85], therefore strenghtening eNOS uncoupling. Finally, it should be noted that: 1) eNOS expression is stimulated by hypercholesterolemia, TNF-alpha, TGF-beta and hypoxia; 2) NADPH oxidase expression is stimulated by glucose, FFA and cytokines in rat pancreatic islets and a clonal beta-cell line [86]; and 3) high glucose levels downregulate the number of monocytic calveolae, which mediate the intracellular lipid transport, through NADPH oxidase-induced OS [87]. The gene encoding the pro-inflammatory/pro-oxidant COX-2 enzyme was strongly up-regulated in GK islets. Notably, inhibition of COX-2 gene or its deletion in macrophages protects against atherosclerosis [88]. Regarding beta-cell function, COX-2 over-expression could be deleterious, because its selective inhibition is able to enhance glucose-induced insulin secretion through a reduction of prostaglandin E2 [89].
###end p 42
###begin p 43
###xml 303 307 303 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Iglarz1">[90]</xref>
###xml 309 313 309 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Dammanahalli1">[91]</xref>
###xml 353 361 353 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 421 425 414 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Helset1">[92]</xref>
###xml 510 517 503 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 551 555 544 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Lai1">[93]</xref>
###xml 694 698 687 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Sachidanandam1">[58]</xref>
###xml 777 781 770 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Leung1">[94]</xref>
###xml 892 896 885 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Higuchi1">[72]</xref>
###xml 947 950 940 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">via</italic>
###xml 968 972 961 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Chen1">[95]</xref>
###xml 1156 1160 1149 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Hodroj1">[96]</xref>
###xml 1278 1282 1271 1275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Daugherty1">[97]</xref>
###xml 1519 1523 1512 1516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Oak1">[98]</xref>
###xml 1649 1653 1639 1643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Shao1">[99]</xref>
###xml 1846 1851 1836 1841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Kamide1">[100]</xref>
###xml 467 472 <span type="species:ncbi:10090">mouse</span>
###xml 627 631 <span type="species:ncbi:10116">rats</span>
###xml 1072 1080 <span type="species:ncbi:9606">patients</span>
###xml 1329 1334 <span type="species:ncbi:10090">mouse</span>
###xml 1534 1539 <span type="species:ncbi:10090">mouse</span>
Among other genes that were found to be up-regulated in diabetic GK islets are those encoding several vasoconstrictor agents, such as ET-1 and RAS-linked molecules. Endothelins activate NADPH oxidases, thereby increasing superoxide production and OS, and consequently leading to endothelial dysfunction [90], [91]. ET-1 has also been shown to stimulate in vitro the release of IL-1beta, TNF-alpha and IL-6 from monocytes [92] and has marked vasoconstrictor effect on mouse pancreatic islet vasculature, either in vivo or in vascularly perfused islets [93]. As already mentioned, circulating ET-1 levels are elevated in aged GK rats and ET-1 antagonists ameliorate their macrovessel alterations [58]. The presence of various RAS components has been described at the islet level [94], and A-II-mediated signal through AGTR-1 involves NADPH activation, superoxide production and eNOS uncoupling [72]. In the diabetic retina, A-II induces leukostasis via NADPH activation [95]. AGT, ACE, and or AGTR-1 mRNA and protein levels are elevated in arterial cells of type 2 diabetic patients, and RAS inhibition reduces the onset of T2D and prevented atherosclerosis [96]. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AGTR-1 [97]. Moreover, in streptozotocin-induced diabetic mouse aortas, the AGTR-1 blocker candesartan or the ACE inhibitor captopril markedly attenuates eNOS-derived ROS production, while augmenting NO bioavailability, implicating eNOS recoupling [98]. In db/db mouse islets, candesartan, ameliorates beta-cell function, decreases OS markers and fibrosis, and prevents EC loss [99]. As expected, GK islets showed an up-regulation of ACE, AGTR-1 genes but an AGT gene down-regulation, which could be linked to the local insulin inhibitory effect on AGT mRNA expression in EC [100].
###end p 43
###begin p 44
###xml 340 345 330 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Ristimaki1">[101]</xref>
###xml 662 667 648 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Ryter1">[102]</xref>
###xml 713 718 699 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Seldon1">[103]</xref>
###xml 767 772 753 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Sacerdoti1">[104]</xref>
###xml 960 965 946 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Becker1">[105]</xref>
###xml 967 972 953 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-vonDobschuetz1">[106]</xref>
###xml 1292 1296 1262 1266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Lacraz2">[80]</xref>
###xml 1375 1380 1341 1346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Hirota1">[107]</xref>
###xml 1723 1728 1685 1690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Adams1">[108]</xref>
###xml 1730 1735 1692 1697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Fadini1">[109]</xref>
###xml 1914 1919 1876 1881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Aicher1">[110]</xref>
###xml 1921 1926 1883 1888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Duda1">[111]</xref>
###xml 1944 1949 1906 1911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Nakao1">[112]</xref>
###xml 2094 2099 2056 2061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Svensson1">[113]</xref>
###xml 955 959 <span type="species:ncbi:10116">rats</span>
###xml 1740 1744 <span type="species:ncbi:10116">rats</span>
###xml 1984 1988 <span type="species:ncbi:10116">rats</span>
###xml 2066 2077 <span type="species:ncbi:10116">Wistar rats</span>
In addition to the up-regulated genes with deleterious effects, we noted a few genes, whose modulation would be supposed to exert protective effects. This is the case for the gene encoding prostacyclin synthase (Ptgis), which is stimulated by IL-1beta, TNF-alpha and TGF-beta, and produces prostacyclin (PGI2), a potent vasodilatator agent [101]. Two other over-expressed genes, also stimulated by cytokines and hypoxia, encode molecules with antioxidant and/or pro-angiogenic effects: HO-1 and HIF-1alpha. HO-1, whose gene expression was markedly up-regulated in GK islets, is a potent antioxidant agent, which is able to decrease MCP-1 but increase VEGF in EC [102], inhibit their adhesion molecules expression [103] and protect them from glucose-induced apoptosis [104]. HO-1 induction improves pancreas graft survival by preventing pancreatitis after transplantation, and protects pancreatic microcirculatory dysfunction after ischemia/reperfusion in rats [105], [106]. HIF-1alpha, like NF-kappaB, is regulated at post-transcriptional and/or post-translational levels. The HIF-1alpha overexpression in GK islets is possibly linked to vessel alterations. We also showed that a crucial target gene of HIF-1alpha, Ldha (encoding lactate deshydrogenase A) was also overexpressed in GK islets [80]. HIF-1alpha regulates several pro-angiogenic genes, eNOS, HO-1, MIF, and VEGF [107]. Because of concomitant gene upregulation of eNOS and HO-1, it is highly probable that HIF-1alpha activity was also stimulated in GK islets. However, VEGF gene expression showed no change. This observation might be of importance in the context of T2D and atherosclerosis, where defects in endothelial precursor cells were recently recognized [108], [109]. GK rats might present a deficient angiogenesis due to lack of VEGF response and also possible eNOS uncoupling, because VEGF-induced-eNOS is an efficient pathway of angiogenesis [110], [111] as well as COX-2 [112]. In this context, the lack for GK rats to increase blood flow and islet mass after 60% pancreatectomy as opposed to Wistar rats should be noted [113].
###end p 44
###begin p 45
###xml 371 375 368 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Larsen1">[29]</xref>
###xml 377 382 374 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Dinarello1">[114]</xref>
###xml 384 389 381 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Perrier1">[115]</xref>
###xml 602 606 599 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Apostolakis1">[31]</xref>
###xml 608 613 605 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Marculescu1">[116]</xref>
###xml 615 620 612 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-vanMinkelen1">[117]</xref>
###xml 750 757 747 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 941 948 935 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 1213 1217 1204 1208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Kim2">[71]</xref>
###xml 1585 1590 1576 1581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Xu1">[118]</xref>
###xml 1696 1703 1687 1694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1938 1944 1929 1935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006963-g003">Fig. 3</xref>
###xml 2087 2092 2078 2083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Jia1">[119]</xref>
###xml 362 370 <span type="species:ncbi:9606">patients</span>
###xml 518 526 <span type="species:ncbi:9606">patients</span>
###xml 1269 1273 <span type="species:ncbi:10116">rats</span>
###xml 1813 1817 <span type="species:ncbi:10116">rats</span>
###xml 2005 2010 <span type="species:ncbi:9606">human</span>
IL-1Ra, the natural IL-1 antagonist, is another molecule of interest in this study for several reasons. It has been shown to: 1) play a crucial role in the prevention of inflammatory diseases; 2) counteract deleterious effects of IL-1 members involved in insulin resistance and diabetes; 3) reduce hyperglycemia and improve beta-cell function in type 2 diabetic patients [29], [114], [115]. In addition, some haplotypes of the IL-1Ra gene have been found to be correlated with increased cardiovascular disease risk in patients with or without diabetes and IL-1Ra is being to be used in atherosclerosis [31], [116], [117]. Compared to Wistar, untreated GK islets showed a marked IL-1Ra gene up-regulation, which was unable to counteract spontaneously in situ the consequences of the concomitant strong IL-1beta gene up-regulation. In this regard, on can note that: 1) a very high IL-1Ra/IL-1 ratio is necessary to counteract IL-1 effects; 2) in situ a very low IL-1beta concentration can exert its pleiotropic action and part of the latter may become IL-1-independent with time; 3) and/or the GK islet inflammatory process could be triggered concomitantly by other factors, such as TLR activation via dyslipidemia [71]. By contrast, 100 mg/kg/day IL-1Ra treatment of GK rats was able to significantly down-regulate most selected genes for endothelial activation, all cytokines/chemokines and their pathways, myeloid cell infiltration, and ECM proteins. Concomitantly, most antioxidant gene expression was down-regulated, particularly those known to be activated by IL-1 at the EC level [118] and serum level of the antioxidant PON-1 was back to age-matched (8-week-old) Wistar values after IL-1Ra in vivo (data not shown). As expected, IL-1Ra treatment reduced islet hyper-vascularisation and islet fibrosis in GK rats. These data highlight the primary role of IL-1 in the pathogenesis of islet microangiopathy in a spontaneous T2D model (Fig. 3). In this regard, co-expression of IL-1Ra and VEGF improves human islet survival, which is strictly dependent upon adequate revascularization [119].
###end p 45
###begin p 46
###xml 89 93 89 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Ehses3">[52]</xref>
###xml 290 294 287 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Sauter1">[30]</xref>
###xml 629 634 619 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Wadt1">[120]</xref>
###xml 635 640 625 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Borjesson1">[123]</xref>
###xml 199 203 <span type="species:ncbi:10116">rats</span>
###xml 284 289 <span type="species:ncbi:10090">mouse</span>
###xml 648 652 <span type="species:ncbi:10116">rats</span>
Concerning IL-1Ra-induced islet endocrine modifications, we recently described elsewhere [52]: 1) no change of the percentage of pancreatic beta-cell area between sham (saline) and IL-1ra-treated GK rats, which would be in agreement with data published on the high fat diet (HFD) fed mouse [30]; 2) IL-1Ra enhancement of the expression of insulin processing enzymes, proconvertase 1 and 2, concomitant with increased insulin gene expression (INS1 and INS2): indeed, IL-1beta downregulates both proconvertase expression, impairing insulin processing, either alone or in combination with other cytokines such as IL-6 and TNF-alpha [120]-[123]. In GK rats, IL-1Ra reduces islet IL-1beta, IL-6, and TNF-alpha mRNAs and IL-6 production, likely improving insulin processing, as reflected by their better circulating pro-insulin/insulin ratio.
###end p 46
###begin p 47
###xml 437 441 437 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Ehses3">[52]</xref>
###xml 721 726 713 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Ellingsgaard1">[124]</xref>
###xml 909 914 893 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Movassat1">[125]</xref>
###xml 940 947 924 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1067 1071 1051 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Ehses3">[52]</xref>
###xml 1296 1300 1280 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Ehses3">[52]</xref>
###xml 716 720 <span type="species:ncbi:10090">mice</span>
###xml 858 862 <span type="species:ncbi:10116">rats</span>
###xml 1223 1227 <span type="species:ncbi:10116">rats</span>
The beneficial effects of IL-1Ra concerning GK glucose homeostasis appears to be somehow limited based on the glycemia values measured at the end of treatment, as shown here. However: 1) the effect of IL-1Ra on glycemia varied greatly from one day to another, despite our attempt to control as best as possible environmental conditions, but the highest dose of IL-1Ra (100 mg/kg/day) administered during 1 month decreased the AUC by 50% [52]; 2) glycemia is the result of insulin production and action and involvement of counterregulatory hormones, notably from from alpha-cells. In this regard, because increased IL-6 release by GK islets may have increase their alpha-cell mass, as described in response to HFD in mice [124], IL-1Ra, which reduced GK islet IL-6 release, might have consequently diminish their alpha-cell mass. However, adult Wistar and GK rats have similar alpha-cell mass and glucagonemia [125] and 100 mg/kg/day IL-1Ra in vivo did not modify GK glucagonemia (data not shown); 3) IL-1Ra appears less effective on insulin resistance at higher dose [52]; 4) the time of treatment onset, the dose and the duration of treatment could be improved; 5) TLR activation by FFA may be concomitantly at work in GK rats and IL-1Ra treatment did not modify circulating GK lipid parameters [52].
###end p 47
###begin p 48
###xml 308 313 308 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Michaelis1">[126]</xref>
###xml 314 319 314 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Spector1">[128]</xref>
###xml 717 722 717 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Node1">[129]</xref>
###xml 882 886 882 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Lacraz1">[44]</xref>
###xml 1074 1079 1074 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Larsen2">[127]</xref>
###xml 1278 1283 1278 1283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Olearczyk1">[130]</xref>
###xml 1285 1290 1285 1290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Ulu1">[131]</xref>
###xml 1525 1530 1525 1530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Larsen2">[127]</xref>
###xml 871 874 <span type="species:ncbi:10116">rat</span>
###xml 1182 1186 <span type="species:ncbi:10116">rats</span>
###xml 1273 1277 <span type="species:ncbi:10090">mice</span>
###xml 1367 1372 <span type="species:ncbi:9606">human</span>
Last but not least, the drastic under-expression of the soluble epoxide hydrolase (sEH) might represent the major attempt to compensate the defects triggered by metabolically-induced inflammation in GK islets. Indeed, sEH is implicated in the metabolism of epoxyeicosatrienoic acids (EETs) (see for reviews, [126]-[128]). These EETs are derived from arachidonic acid by cytochrome P450 epoxygenases. Their degradation by sEH generate dihydroxyeicosatrienoic acids, which are less active than their parent epoxides. Decreased sEH activity would therefore be expected to increase intracellular EET levels and prolong their beneficial effects, which include: 1) potent vasodilatation; 2) marked anti-inflammatory action [129]; 3) antioxidant effect by inducing the expression of a set of antioxidant genes, including thioredoxin and superoxide dismutase, as described in GK rat islets [44]; 4) beneficial effects on vessels: EETs inhibit the migration and proliferation of VSMC and, by contrast, stimulate EC proliferation and angiogenesis, particularly in response to hypoxia [127]. Very recent data showed that sEH inhibitors attenuate the progression of renal damage in diabetic GK rats from Taconic and also the development of atherosclerosis in apolipoprotein-E-knockout mice [130], [131]. Moreover, it has been described several polymorphisms in the gene encoding human sEH that encode variants with altered catalytic activity. Some of these variants are associated with increased risk of atherosclerosis (for review, see [127]).
###end p 48
###begin p 49
###xml 409 413 <span type="species:ncbi:10116">rats</span>
In conclusion, these data offer a better understanding of the pathophysiology of islet behaviour in a spontaneous T2D animal model, where both pro- and anti-vasoconstrictor, pro- and antioxidant, pro- and anti-inflammatory, and pro- and anti-angiogenic mechanisms are concomitantly at play in islets during disease progression. The protective mechanisms may thus explain long-lasting mild hyperglycemia in GK rats, despite early islet endothelial activation associated with inflammation and OS. These data also highlight the crucial role of IL-1 in triggering islet OS. Therefore, counteracting endothelial cell inflammation as early as possible is one way to prevent OS-related disorders in type 2 diabetes pathophysiology.
###end p 49
###begin title 50
Methods
###end title 50
###begin title 51
Animals
###end title 51
###begin p 52
###xml 432 436 432 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Portha1">[32]</xref>
###xml 81 92 <span type="species:ncbi:10116">Wistar rats</span>
###xml 289 292 <span type="species:ncbi:10116">rat</span>
###xml 396 400 <span type="species:ncbi:10116">rats</span>
###xml 468 472 <span type="species:ncbi:10116">rats</span>
All animal experiments were conducted on fed age-matched male GK and nondiabetic Wistar rats from our local colonies (Paris, France) in accordance with accepted standards of animal care, established by the French National Center for Scientific Research. Characteristics of the nonobese GK rat model of T2D maintained in our colony at the University Paris-Diderot together with the Wistar control rats have been previously described [32]. Two and a half-month-old male rats were killed by decapitation and blood and pancreata collected for measurement of metabolic parameters, islet isolation and quantitative RT-PCR analysis or pancreas immunohistochemistry.
###end p 52
###begin title 53
Metabolic parameters
###end title 53
###begin p 54
###xml 804 809 786 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Melnyk1">[132]</xref>
###xml 1159 1164 1131 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Galinier1">[133]</xref>
###xml 1257 1262 1229 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Fortin1">[134]</xref>
###xml 1459 1460 1427 1428 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1840 1845 1799 1804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Ellingsgaard1">[124]</xref>
Basal morning glycemia was determined with a glucometer. Serum insulin was assayed by ELISA (Mercodia). FFA levels were quantified using an enzymatic colorimetric assay (NEFA C) (Wako Chemicals GmbH). Cholesterol, HDL, and triglyceride serum levels were determined by using colorimetric assays (Penta Cholesterol CP kit, HDL cholesterol direct kit and Pentra Triglycerid CP kit, respectively, ABX Diagnostics). To measure glutathione, 50 microl of RBC were added to 450 microl of a mixture (1:5 v/v) of EDTA (1%)/metaphosphoric acid (5%), and 100 or 200 islets were mixed with 5% metaphosphoric acid (300 microl). After centrifugation (3000 g, 10 min, 4degreesC), reduced glutathione (GSH) and its oxidized form (GSSG) were identified in supernatants by reverse-phase HPLC with electrochemical detection [132]). Total glutathione content, referred to as "equivalent GSH" (Eq GSH), is the sum of GSH and doubled GSSG concentrations (2GSH-->GSSG). The glutathione redox state is: [total forms] x100, with [total forms]  =  [oxidized form]+[reduced form]. Alpha-tocopherol was determined in heparinated plasma (100 microl) extracted with 2-propanol (400 microl) [133]. Plasma homocysteine was assayed by using the fluorimetric HPLC method previously described [134]. PON-1 activity assay was performed on 5 microl of plasma. PON-1 arylesterase activity toward phenyl acetate was quantified spectrophotometrically using 20 mM of Tris-HCl, pH 8.3 with 1 mM of CaCl2 and 10 mM of phenyl acetate (Sigma-Aldrich). The reaction was performed at room temperature for 1 min by measuring the appearance of phenol at 270 nm with the use of continuously and automated recording spectrophotometer. All values were corrected for non-enzymatic hydrolysis. Serum leptin, cytokines and chemokines were assayed using Luminextrade mark (Millipore, Switzerland) [124].
###end p 54
###begin title 55
Islet isolation and mRNA analysis
###end title 55
###begin p 56
###xml 117 122 117 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Giroix1">[135]</xref>
###xml 634 641 630 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006963-t003">Table 3</xref>
###xml 1166 1167 1138 1139 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 589 592 <span type="species:ncbi:10116">rat</span>
Pancreatic islets were isolated using collagenase (Boehringer Mannheim) and then handpicked under a stereomicroscope [135]. Total RNA was isolated from islets using the RNeasy mini kit (Qiagen) and its concentration determined by optical density at 260 nm. To remove residual DNA contamination, the RNA samples were treated with RNAse-free DNAse (Qiagen) and purified with RNeasy mini-column (Qiagen). Total RNA (4 microg) from each islet sample was reverse transcribed with 40 U of M-MLV Reverse Transcriptase (Invitrogen) using random hexamer primers. The primers used were derived from rat sequences and designed using OLIGO6 (see Table 3). Quantitative RT-PCR amplification reactions were carried out in a LightCycler 1.5 detection system (Roche) using the LightCycler FastStart DNA Master plus SYBR Green I kit (Roche). Reverse transcribed RNA (10 ng) was used as the template for each reaction. All reactions were run in duplicate with no template control. The PCR conditions were: 95degreesC for 10 min, followed by 40 cycles at 95degreesC for 10 s, 60degreesC for 10 s and 72degreesC for 10 s. Changes in mRNA expression were calculated using difference of CT values as compared to a housekeeping gene (rpL19 or Ef1a), and expressed relative to controls.
###end p 56
###begin title 57
Primer oligonucleotide sequences of selected genes.
###end title 57
###begin title 58
In vivo IL-1Ra treatment
###end title 58
###begin p 59
###xml 245 249 245 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-Portha1">[32]</xref>
###xml 58 62 <span type="species:ncbi:10116">rats</span>
IL-1Ra (kindly donated by Amgen, CA, USA) treatment of GK rats was performed by twice daily subcutaneous injections (100 mg/kg/day). Treatment was initiated 3 days following weaning at 4 weeks of age, i.e., after onset of mild fed hyperglycemia [32]. IL-1Ra treatment, which was given during growth of the animals, had no effect on body weight. Subcutaneous (s.c.) injection experiments were stopped 4 weeks after initiation of treatment and the animals sacrificed for islet isolation followed by quantitative RT-PCR or pancreas immunohistochemistry.
###end p 59
###begin title 60
Immunohistochemistry
###end title 60
###begin p 61
###xml 211 214 211 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006963-HomoDelarche1">[6]</xref>
###xml 3 6 <span type="species:ncbi:10116">rat</span>
###xml 51 57 <span type="species:ncbi:9986">rabbit</span>
###xml 94 100 <span type="species:ncbi:9986">rabbit</span>
###xml 147 153 <span type="species:ncbi:9986">rabbit</span>
GK rat pancreatic cryosections were incubated with rabbit anti-fibronectin (1/40, Novotec) or rabbit anti-VWF (1/100, Dako), followed by swin anti-rabbit secondary antibody (1/100, Dako) as previously described [6]. Antibody-stained surface areas were quantified blindly by measuring the surface area labeled by each marker in a given islet and expressing it to the whole surface of this islet (in 25-40 islets in 3 animals per treatment group), using an Olympus BX40 microscope.
###end p 61
###begin title 62
Statistics
###end title 62
###begin p 63
###xml 83 84 81 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Data are presented as means+/-SEM. Statistical analyses used an unpaired Student's t-test or ANOVA as appropriate. Significance was defined as p<0.05.
###end p 63
###begin p 64
We thank M. Borsig and D. Bailbe for technical assistance.
###end p 64
###begin title 65
References
###end title 65
###begin article-title 66
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I.
###end article-title 66
###begin article-title 67
Biochemistry and molecular cell biology of diabetic complications.
###end article-title 67
###begin article-title 68
Isletopathy in Type 2 diabetes mellitus: implications of islet RAS, islet fibrosis, islet amyloid, remodeling, and oxidative stress.
###end article-title 68
###begin article-title 69
Loss of beta-cells with fibrotic islet destruction in type 2 diabetes mellitus.
###end article-title 69
###begin article-title 70
Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes?
###end article-title 70
###begin article-title 71
###xml 82 85 <span type="species:ncbi:10116">rat</span>
Islet inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat.
###end article-title 71
###begin article-title 72
Islet inflammation in type 2 diabetes (T2D): from endothelial to beta-cell dysfunction.
###end article-title 72
###begin article-title 73
Increased number of islet-associated macrophages in type 2 diabetes.
###end article-title 73
###begin article-title 74
Islet inflammation in type 2 diabetes: from metabolic stress to therapy.
###end article-title 74
###begin article-title 75
###xml 55 59 <span type="species:ncbi:10090">mice</span>
The endocrine pancreas of spontaneously diabetic db/db mice: microangiopathy as revealed by transmission electron microscopy.
###end article-title 75
###begin article-title 76
Islet microvasculature in islet hyperplasia and failure in a model of type 2 diabetes.
###end article-title 76
###begin article-title 77
Diabetes and endothelial dysfunction: a clinical perspective.
###end article-title 77
###begin article-title 78
Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells.
###end article-title 78
###begin article-title 79
Oxidative stress at the vascular wall. Mechanistic and pharmacological aspects.
###end article-title 79
###begin article-title 80
PPARgamma and atherosclerosis.
###end article-title 80
###begin article-title 81
Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited.
###end article-title 81
###begin article-title 82
The pathobiology of diabetic complications: a unifying mechanism.
###end article-title 82
###begin article-title 83
Vascular complications in diabetes mellitus: the role of endothelial dysfunction.
###end article-title 83
###begin article-title 84
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage.
###end article-title 84
###begin article-title 85
###xml 52 60 <span type="species:ncbi:9606">patients</span>
Lipid peroxidation and serum antioxidant enzymes in patients with type 2 diabetes mellitus.
###end article-title 85
###begin article-title 86
###xml 86 92 <span type="species:ncbi:9606">people</span>
Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome.
###end article-title 86
###begin article-title 87
Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein.
###end article-title 87
###begin article-title 88
Cytokine regulation of endothelial cell function.
###end article-title 88
###begin article-title 89
Adenoviral overexpression of the glutamylcysteine ligase catalytic subunit protects pancreatic islets against oxidative stress.
###end article-title 89
###begin article-title 90
Role of oxidative modifications in atherosclerosis.
###end article-title 90
###begin article-title 91
Redox events in interleukin-1 signaling.
###end article-title 91
###begin article-title 92
NF-kappaB activation by reactive oxygen species: fifteen years later.
###end article-title 92
###begin article-title 93
Cytokines in atherosclerosis: pathogenic and regulatory pathways.
###end article-title 93
###begin article-title 94
Interleukin-1-receptor antagonist in type 2 diabetes mellitus.
###end article-title 94
###begin article-title 95
The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia.
###end article-title 95
###begin article-title 96
IL-1 cytokines in cardiovascular disease: diagnostic, prognostic and therapeutic implications.
###end article-title 96
###begin article-title 97
###xml 7 10 <span type="species:ncbi:10116">rat</span>
###xml 51 56 <span type="species:ncbi:9606">human</span>
The GK rat beta-cell: a prototype for the diseased human beta-cell in type 2 diabetes?
###end article-title 97
###begin article-title 98
Does homocysteine promote atherosclerosis?
###end article-title 98
###begin article-title 99
###xml 99 110 <span type="species:ncbi:10116">Wistar rats</span>
Effect of hyperhomocysteinemia on cardiovascular risk factors and initiation of atherosclerosis in Wistar rats.
###end article-title 99
###begin article-title 100
###xml 98 102 <span type="species:ncbi:10090">mice</span>
Homocysteine threshold value based on cystathionine beta synthase and paraoxonase 1 activities in mice.
###end article-title 100
###begin article-title 101
###xml 121 125 <span type="species:ncbi:10090">mice</span>
Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E.
###end article-title 101
###begin article-title 102
Functional role for toll-like receptors in atherosclerosis and arterial remodeling.
###end article-title 102
###begin article-title 103
Chemokine regulation of atherosclerosis.
###end article-title 103
###begin article-title 104
Modulation of endothelial cell functions by different molecular species of interleukin 1.
###end article-title 104
###begin article-title 105
Cytokine regulation of endothelial cell function: from molecular level to the bedside.
###end article-title 105
###begin article-title 106
###xml 134 139 <span type="species:ncbi:10090">mouse</span>
CuZn-superoxide dismutase, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse.
###end article-title 106
###begin article-title 107
###xml 88 93 <span type="species:ncbi:10090">mouse</span>
Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues.
###end article-title 107
###begin article-title 108
Increased expression of antioxidant and antiapoptotic genes in islets that may contribute to beta-cell survival during chronic hyperglycemia.
###end article-title 108
###begin article-title 109
Diabetic beta-cells can achieve self-protection against oxidative stress through an adaptative up-regulation of their antioxidant defenses.
###end article-title 109
###begin article-title 110
L-gamma-Glutamyl-L-cysteinyl-glycine (glutathione; GSH) and GSH-related enzymes in the regulation of pro- and anti-inflammatory cytokines: a signaling transcriptional scenario for redox(y) immunologic sensor(s)?
###end article-title 110
###begin article-title 111
###xml 32 35 <span type="species:ncbi:10116">rat</span>
Haeme-oxygenase 1 expression in rat pancreatic beta cells is stimulated by supraphysiological glucose concentrations and by cyclic AMP.
###end article-title 111
###begin article-title 112
Heme oxygenase: a novel target for the modulation of the inflammatory response.
###end article-title 112
###begin article-title 113
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy.
###end article-title 113
###begin article-title 114
###xml 96 101 <span type="species:ncbi:9606">human</span>
Effect of tumor necrosis factor-alpha and interleukin-1 alpha on heme oxygenase-1 expression in human endothelial cells.
###end article-title 114
###begin article-title 115
Induction of heme oxygenase-1 inhibits the monocyte transmigration induced by mildly oxidized LDL.
###end article-title 115
###begin article-title 116
Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival.
###end article-title 116
###begin article-title 117
###xml 88 91 <span type="species:ncbi:10116">rat</span>
IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat.
###end article-title 117
###begin article-title 118
###xml 92 96 <span type="species:ncbi:10116">rats</span>
Chronological characterization of diabetes development in male Spontaneously Diabetic Torii rats.
###end article-title 118
###begin article-title 119
###xml 82 86 <span type="species:ncbi:10116">rats</span>
Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats.
###end article-title 119
###begin article-title 120
###xml 96 100 <span type="species:ncbi:10116">rats</span>
Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats.
###end article-title 120
###begin article-title 121
Nitric oxide dynamics and endothelial dysfunction in type II model of genetic diabetes.
###end article-title 121
###begin article-title 122
Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1.
###end article-title 122
###begin article-title 123
Evidence for vasculoprotective effects of ETB receptors in resistance artery remodeling in diabetes.
###end article-title 123
###begin article-title 124
###xml 29 31 29 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 133 137 <span type="species:ncbi:10116">rats</span>
Supplementation of Coenzyme Q10 and alpha-tocopherol lowers glycated hemoglobin level and lipid peroxidation in pancreas of diabetic rats.
###end article-title 124
###begin article-title 125
###xml 68 72 <span type="species:ncbi:10116">rats</span>
Glycated serum stimulation of macrophages in GK- and streptozotocin-rats for the proliferation of primary cultured smooth muscle cells of the aorta.
###end article-title 125
###begin article-title 126
###xml 127 130 <span type="species:ncbi:10116">rat</span>
###xml 177 180 <span type="species:ncbi:10116">rat</span>
Enhanced insulin secretion and cholesterol metabolism in congenic strains of the spontaneously diabetic (Type 2) Goto Kakizaki rat are controlled by independent genetic loci in rat chromosome 8.
###end article-title 126
###begin article-title 127
###xml 132 136 <span type="species:ncbi:10116">rats</span>
Genetic control of plasma lipid levels in a cross derived from normoglycaemic Brown Norway and spontaneously diabetic Goto-Kakizaki rats.
###end article-title 127
###begin article-title 128
Leptin and atherosclerosis.
###end article-title 128
###begin article-title 129
The antiatherogenic function of HDL is impaired in hyperhomocysteinemic subjects.
###end article-title 129
###begin article-title 130
Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase.
###end article-title 130
###begin article-title 131
Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.
###end article-title 131
###begin article-title 132
###xml 56 60 <span type="species:ncbi:10090">mice</span>
Paraoxonase 1 (PON1) attenuates diabetes development in mice through its antioxidative properties.
###end article-title 132
###begin article-title 133
Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia.
###end article-title 133
###begin article-title 134
High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells.
###end article-title 134
###begin article-title 135
Hyperglycemia-induced reactive oxygen species toxicity to endothelial cells is dependent on paracrine mediators.
###end article-title 135
###begin article-title 136
Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity.
###end article-title 136
###begin article-title 137
Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology.
###end article-title 137
###begin article-title 138
Reactive nitrogen species in the chemical biology of inflammation.
###end article-title 138
###begin article-title 139
Cytokines and beta-cell biology: from concept to clinical translation.
###end article-title 139
###begin article-title 140
###xml 108 112 <span type="species:ncbi:10116">rats</span>
Glucose intolerance and hyperlipidemia prior to diabetes onset in female Spontaneously Diabetic Torii (SDT) rats.
###end article-title 140
###begin article-title 141
###xml 86 89 <span type="species:ncbi:10116">rat</span>
The prediabetic period is characterized by islet microangiopathy in the Goto-Kakizaki rat, a spontaneous model of type 2 diabetes.
###end article-title 141
###begin article-title 142
###xml 119 122 <span type="species:ncbi:10116">rat</span>
Defective IGF2 and IGF1R protein production in embryonic pancreas precedes beta cell mass anomaly in the Goto-Kakizaki rat model of type 2 diabetes.
###end article-title 142
###begin article-title 143
Inflammation and cardiovascular disease mechanisms.
###end article-title 143
###begin article-title 144
Caspase-1 inflammasomes in infection and inflammation.
###end article-title 144
###begin article-title 145
###xml 41 44 <span type="species:ncbi:10116">rat</span>
Beta cells of the diabetic Goto-kakizaki rat exhibit an unexpected in vitro adaptation to oxidative stress-induced apoptosis.
###end article-title 145
###begin article-title 146
###xml 91 95 <span type="species:ncbi:10090">mice</span>
Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes.
###end article-title 146
###begin article-title 147
###xml 18 23 <span type="species:ncbi:9606">human</span>
Overexpression of human copper, zinc-superoxide dismutase (SOD1) prevents postischemic injury.
###end article-title 147
###begin article-title 148
The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology.
###end article-title 148
###begin article-title 149
###xml 81 86 <span type="species:ncbi:10090">mouse</span>
Increased oxidative stress in the streptozotocin-induced diabetic apoE-deficient mouse: changes in expression of NADPH oxidase subunits and eNOS.
###end article-title 149
###begin article-title 150
###xml 52 56 <span type="species:ncbi:10116">rats</span>
Excessive islet NO generation in type 2 diabetic GK rats coincides with abnormal hormone secretion and is counteracted by GLP-1.
###end article-title 150
###begin article-title 151
###xml 120 123 <span type="species:ncbi:10116">rat</span>
Glucose, palmitate and pro-inflammatory cytokines modulate production and activity of a phagocyte-like NADPH oxidase in rat pancreatic islets and a clonal beta cell line.
###end article-title 151
###begin article-title 152
High glucose downregulates the number of caveolae in monocytes through oxidative stress from NADPH oxidase: implications for atherosclerosis.
###end article-title 152
###begin article-title 153
Cyclooxygenase-2 and inflammation in atherosclerosis.
###end article-title 153
###begin article-title 154
###xml 116 120 <span type="species:ncbi:10090">mice</span>
Effect of selective cyclooxygenase-2 (COX-2) inhibitor treatment on glucose-stimulated insulin secretion in C57BL/6 mice.
###end article-title 154
###begin article-title 155
Mechanisms of ET-1-induced endothelial dysfunction.
###end article-title 155
###begin article-title 156
Endothelins and NADPH oxidases in the cardiovascular system.
###end article-title 156
###begin article-title 157
###xml 24 29 <span type="species:ncbi:9606">human</span>
Endothelin-1 stimulates human monocytes in vitro to release TNF-alpha, IL-1beta and IL-6.
###end article-title 157
###begin article-title 158
Endothelin-1 and pancreatic islet vasculature: studies in vivo and on isolated, vascularly perfused pancreatic islets.
###end article-title 158
###begin article-title 159
The physiology of a local renin-angiotensin system in the pancreas.
###end article-title 159
###begin article-title 160
Role of NADPH oxidase and ANG II in diabetes-induced retinal leukostasis.
###end article-title 160
###begin article-title 161
###xml 103 111 <span type="species:ncbi:9606">patients</span>
Increased insulin-stimulated expression of arterial angiotensinogen and angiotensin type 1 receptor in patients with type 2 diabetes mellitus and atheroma.
###end article-title 161
###begin article-title 162
Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor.
###end article-title 162
###begin article-title 163
###xml 108 112 <span type="species:ncbi:10090">mice</span>
Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice.
###end article-title 163
###begin article-title 164
###xml 124 128 <span type="species:ncbi:10090">mice</span>
Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice.
###end article-title 164
###begin article-title 165
Insulin-mediated regulation of the endothelial renin-angiotensin system and vascular cell growth.
###end article-title 165
###begin article-title 166
Modulation of prostacyclin production by cytokines in vascular endothelial cells.
###end article-title 166
###begin article-title 167
Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications.
###end article-title 167
###begin article-title 168
Heme oxygenase-1 inhibits the expression of adhesion molecules associated with endothelial cell activation via inhibition of NF-kappaB RelA phosphorylation at serine 276.
###end article-title 168
###begin article-title 169
Heme oxygenase-1 transduction in endothelial cells causes downregulation of monocyte chemoattractant protein-1 and of genes involved in inflammation and growth.
###end article-title 169
###begin article-title 170
Induction of heme oxygenase-1 improves the survival of pancreas grafts by prevention of pancreatitis after transplantation.
###end article-title 170
###begin article-title 171
###xml 109 113 <span type="species:ncbi:10116">rats</span>
Protective role of heme oxygenase-1 in pancreatic microcirculatory dysfunction after ischemia/reperfusion in rats.
###end article-title 171
###begin article-title 172
Regulation of angiogenesis by hypoxia-inducible factor 1.
###end article-title 172
###begin article-title 173
Stem cell therapy for vascular disease.
###end article-title 173
###begin article-title 174
An underlying principle for the study of circulating progenitor cells in diabetes and its complications.
###end article-title 174
###begin article-title 175
Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells.
###end article-title 175
###begin article-title 176
Role of eNOS in neovascularization: NO for endothelial progenitor cells.
###end article-title 176
###begin article-title 177
Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth.
###end article-title 177
###begin article-title 178
###xml 71 75 <span type="species:ncbi:10116">rats</span>
Lack of compensatory increase in islet blood flow and islet mass in GK rats following 60% partial pancreatectomy.
###end article-title 178
###begin article-title 179
Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation.
###end article-title 179
###begin article-title 180
IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?
###end article-title 180
###begin article-title 181
###xml 90 98 <span type="species:ncbi:9606">patients</span>
Interleukin-1 receptor antagonist genotype is associated with coronary atherosclerosis in patients with type 2 diabetes.
###end article-title 181
###begin article-title 182
Haplotypes of the interleukin-1 receptor antagonist gene, interleukin-1 receptor antagonist mRNA levels and the risk of myocardial infarction.
###end article-title 182
###begin article-title 183
###xml 64 69 <span type="species:ncbi:9606">human</span>
An intronic NF-kappaB element is essential for induction of the human manganese superoxide dismutase gene by tumor necrosis factor-alpha and interleukin-1beta.
###end article-title 183
###begin article-title 184
###xml 102 107 <span type="species:ncbi:9606">human</span>
Coexpression of vascular endothelial growth factor and interleukin-1 receptor antagonist for improved human islet survival and function.
###end article-title 184
###begin article-title 185
###xml 87 90 <span type="species:ncbi:10116">rat</span>
Ciliary neurotrophic factor potentiates the beta-cell inhibitory effect of IL-1beta in rat pancreatic islets associated with increased nitric oxide synthesis and increased expression of inducible nitric oxide synthase.
###end article-title 185
###begin article-title 186
###xml 12 17 <span type="species:ncbi:9606">human</span>
Exposure of human islets to cytokines can result in disproportionately elevated proinsulin release.
###end article-title 186
###begin article-title 187
###xml 88 94 <span type="species:ncbi:10090">murine</span>
Cytokines affect PDX-1 expression, insulin and proinsulin secretion from iNOS deficient murine islets.
###end article-title 187
###begin article-title 188
###xml 33 36 <span type="species:ncbi:10116">rat</span>
Altered proinsulin conversion in rat pancreatic islets exposed long-term to various glucose concentrations or interleukin-1beta.
###end article-title 188
###begin article-title 189
Interleukin-6 regulates pancreatic alpha-cell mass expansion.
###end article-title 189
###begin article-title 190
###xml 114 117 <span type="species:ncbi:10116">rat</span>
Impaired development of pancreatic beta-cell mass is a primary event during the progression to diabetes in the GK rat.
###end article-title 190
###begin article-title 191
From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: Epoxyeicosatrienoic acids (EETs) and cell signaling.
###end article-title 191
###begin article-title 192
Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system.
###end article-title 192
###begin article-title 193
Action of epoxyeicosatrienoic acids on cellular function.
###end article-title 193
###begin article-title 194
Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.
###end article-title 194
###begin article-title 195
###xml 148 152 <span type="species:ncbi:10116">rats</span>
Administration of a substituted adamantly-urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats.
###end article-title 195
###begin article-title 196
###xml 108 113 <span type="species:ncbi:10090">mouse</span>
Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model.
###end article-title 196
###begin article-title 197
A new HPLC method for the simultaneous determination of oxidized and reduced plasma aminothiols using coulometric electrochemical detection.
###end article-title 197
###begin article-title 198
###xml 76 80 <span type="species:ncbi:10116">rats</span>
Site specific changes of redox metabolism in adipose tissue of obese Zucker rats.
###end article-title 198
###begin article-title 199
Measurement of homocyst(e)ine in the prediction of arteriosclerosis.
###end article-title 199
###begin article-title 200
###xml 81 84 <span type="species:ncbi:10116">rat</span>
Functional and metabolic perturbations in isolated pancreatic islets from the GK rat, a genetic model of noninsulin-dependent diabetes.
###end article-title 200
###begin p 201
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: M.Y.D is a consultant for Amgen, XOMA, Novartis, and Merck. M.Y.D is listed as the inventor on a patent (WO6709) filed in 2003 for the use of an interleukin-1 receptor antagonist for the treatment of or prophylaxis against type 2 diabetes. The patent is owned by the University of Zurich, and M.Y.D. has no financial interest in the patent. There are no other potential competing interests.
###end p 201
###begin p 202
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by grants from Centre National de la Recherche Scientifique (B.P, F.H.D, M.-H.G), the Swiss National Science Foundation (M.Y.D), the European Foundation for the Study of Diabetes (EASD/MSD for F.H.D. and M.Y.D), the Juvenile Diabetes Research Foundation (M.Y.D). G. Lacraz received a doctoral fellowship from the Ministere de l'Education Nationale, de l'Enseignement Superieur et de la Recherche (Ecole Doctorale 394, Physiologie/Physiopathologie). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 202

